Ancient lion
Thank your creator
- Nov 22, 2010
- 3,100
- 969
- 200
The final results from a phase 3 trial of a recombinant, replication-competent vesicular stomatitis virus–based candidate vaccine:
http://www.medscape.com/viewarticle/873719?nlid=111682_2243These findings, published online December 22 in the Lancet, are the final results from a phase 3 trial of a recombinant, replication-competent vesicular stomatitis virus–based candidate vaccine expressing a surface glycoprotein, dubbed rVSV-ZEBOV. The same issue also includes successful results from a phase 2 trial, led by Feng-Cai Zhu, MSc, from the Jiangsu Provincial Center for Disease Control and Prevention in Nanjing, China, and Alie H Wurie, MSc, from the Ministry of Health and Sanitation in Freetown, Sierra Leone, of another vaccine candidate: recombinant adenovirus type-5 vector-based vaccine expressing the glycoprotein of Ebola Zaire Makona Variant.